MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Milestone Pharmaceuticals Inc (MIST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA approval of its key product Cardamyst, multiple analyst upgrades with price targets significantly above the current price, and a clean label for its product. Despite weak technical indicators and financial performance, the long-term growth potential and positive sentiment make it a favorable investment for this user scenario.
The technical indicators are mixed to bearish. The MACD is positive but contracting, RSI is neutral at 20.055, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.606 and 1.552, with resistance at 1.694 and 1.782. The stock is trading below its pivot point, suggesting limited short-term momentum.
FDA approval of Cardamyst for paroxysmal supraventricular tachycardia with a clean label and no market-limiting warnings.
Analysts have raised price targets to $8, significantly above the current price of $1.
Cardamyst's commercial launch strategy and pricing are expected to drive strong revenue growth.
Multiple analyst upgrades to Buy ratings.
Weak financial performance with negative net income (-$11.92M) and declining EPS (-14.29% YoY).
Bearish technical indicators and a high probability of short-term price decline based on historical patterns.
No significant hedge fund or insider trading activity to support bullish momentum.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of $11.92M (improved by 26.31% YoY), and a decline in EPS by -14.29% YoY. Gross margin remains at 0%. Financials indicate weak performance but potential for improvement with the launch of Cardamyst.
Analysts are highly bullish on MIST. Wells Fargo, H.C. Wainwright, and TD Cowen have all raised price targets to $8 and upgraded the stock to Buy or Overweight. Analysts cite the FDA approval of Cardamyst, its clean label, and strong commercial potential as key drivers for their optimism.
